keyword
MENU ▼
Read by QxMD icon Read
search

TAVR

keyword
https://www.readbyqxmd.com/read/28533099/surgical-aortic-valve-replacement-following-early-sapien-xt-valve-failure-a-first
#1
Tanveer Ahmad, Prakash Ludhani, Ronen Gurvitch, John Goldblatt, James Tatoulis
BACKGROUND: Early degeneration of prosthetic aortic valve in transcatheter aortic valve replacement (TAVR) is a rare complication. METHOD: We report the case of a 75-year-old woman who presented with severe calcific stenosis of Edwards SAPIEN-XT valve implanted only four years previously. She is a Jehovah's Witness and has background of Sjogren's syndrome with secondary cryoglobulinaemic vasculitis. She was not a suitable candidate for valve-in-valve TAVR in view of early prosthetic valve failure by calcification...
May 9, 2017: Heart, Lung & Circulation
https://www.readbyqxmd.com/read/28532778/review-of-major-registries-and-clinical-trials-of-late-outcomes-after-transcatheter-aortic-valve-replacement
#2
REVIEW
Sameer Arora, Cassandra J Ramm, Paula D Strassle, Satyanarayana R Vaidya, Thomas G Caranasos, John P Vavalle
The results of the Placement of AoRtic TraNscathetER Valves (PARTNER) 2 trial established the feasibility of transcatheter aortic valve replacement (TAVR) for intermediate surgical risk patients. The expansion of TAVR into the low-risk patient population will largely depend on its durability outcomes due to the high life expectancy in low-risk patients. Long-term follow-up results from low-risk clinical trials will take several years to be reported. Given this, we performed a systematic review of current long-term data to provide further insights into TAVR durability and long-term patient survival...
April 27, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28528156/prognostic-impact-of-low-flow-severe-aortic-stenosis-in-small-body-patients-undergoing-tavr-the-ocean-tavi-registry
#3
Akihisa Kataoka, Yusuke Watanabe, Ken Kozuma, Yugo Nara, Fukuko Nagura, Hideyuki Kawashima, Hirofumi Hioki, Makoto Nakashima, Masanori Yamamoto, Kensuke Takagi, Motoharu Araki, Norio Tada, Shinichi Shirai, Futoshi Yamanaka, Kentaro Hayashida
OBJECTIVES: This study aimed to analyze the prognostic impact of low-flow (LF) severe aortic stenosis in small-body patients undergoing transcatheter aortic valve replacement (TAVR). BACKGROUND: Western literature demonstrates a poor prognosis with paradoxical LF and low-flow low-gradient (LF-LG) severe aortic stenosis (AS), as defined by stroke volume index (SVi) <35 ml/m(2) and mean pressure gradient <40 mm Hg with preserved left ventricular ejection fraction (LVEF)...
May 11, 2017: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/28527771/aspirin-versus-aspirin-plus-clopidogrel-as-antithrombotic-treatment-following-transcatheter-aortic-valve-replacement-with-a-balloon-expandable-valve-the-arte-aspirin-versus-aspirin%C3%A2-clopidogrel-following%C3%A2-transcatheter-aortic-valve-implantation-randomized%C3%A2
#4
Josep Rodés-Cabau, Jean-Bernard Masson, Robert C Welsh, Bruno Garcia Del Blanco, Marc Pelletier, John G Webb, Faisal Al-Qoofi, Philippe Généreux, Gabriel Maluenda, Martin Thoenes, Jean-Michel Paradis, Chekrallah Chamandi, Vicenç Serra, Eric Dumont, Mélanie Côté
OBJECTIVE: The aim of this study was to compare aspirin plus clopidogrel with aspirin alone as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the prevention of ischemic events, bleeding events, and death. BACKGROUND: Few data exist on the optimal antithrombotic therapy following TAVR. METHODS: This was a randomized controlled trial comparing aspirin (80 to 100 mg/day) plus clopidogrel (75 mg/day) (dual-antiplatelet therapy [DAPT]) versus aspirin alone (single-antiplatelet therapy [SAPT]) in patients undergoing TAVR with a balloon-expandable valve...
May 11, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28521924/tavr-for-pure-native-aortic-regurgitation%C3%A2-and-failing-regurgitant%C3%A2-surgical-bioprostheses-alternative-indication-or-alternative-fact
#5
EDITORIAL
Sameer Gafoor, Rahul Sharma
No abstract text is available yet for this article.
May 22, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28521923/safety-and-efficacy-of-transcatheter-aortic-valve-replacement-in-the-treatment-of-pure-aortic-regurgitation-in-native-valves-and-failing-surgical-bioprostheses-results-from-an-international-registry-study
#6
Fadi J Sawaya, Marcus-André Deutsch, Moritz Seiffert, Sung-Han Yoon, Pablo Codner, Upul Wickramarachchi, Azeem Latib, A Sonia Petronio, Josep Rodés-Cabau, Maurizio Taramasso, Marco Spaziano, Johan Bosmans, Luigi Biasco, Darren Mylotte, Mikko Savontaus, Peter Gheeraert, Jason Chan, Troels H Jørgensen, Horst Sievert, Marco Mocetti, Thierry Lefèvre, Francesco Maisano, Antonio Mangieri, David Hildick-Smith, Ran Kornowski, Raj Makkar, Sabine Bleiziffer, Lars Søndergaard, Ole De Backer
OBJECTIVES: The aim of this study was to evaluate the use of transcatheter heart valves (THV) for the treatment of noncalcific pure native aortic valve regurgitation (NAVR) and failing bioprosthetic surgical heart valves (SHVs) with pure severe aortic regurgitation (AR). BACKGROUND: Limited data are available about the "off-label" use of transcatheter aortic valve replacement (TAVR) to treat pure severe AR. METHODS: The study population consisted of patients with pure severe AR treated by TAVR at 18 different centers...
May 22, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28521921/1-year-results-in-patients-undergoing-transcatheter-aortic-valve-replacement-with-failed-surgical-bioprostheses
#7
G Michael Deeb, Stanley J Chetcuti, Michael J Reardon, Himanshu J Patel, P Michael Grossman, Theodore Schreiber, John K Forrest, Tanvir K Bajwa, Daniel P O'Hair, George Petrossian, Newell Robinson, Stanley Katz, Alan Hartman, Harold L Dauerman, Joseph Schmoker, Kamal Khabbaz, Daniel R Watson, Steven J Yakubov, Jae K Oh, Shuzhen Li, Neal S Kleiman, David H Adams, Jeffrey J Popma
OBJECTIVES: This study evaluated the safety and effectiveness of self-expanding transcatheter aortic valve replacement (TAVR) in patients with surgical valve failure (SVF). BACKGROUND: Self-expanding TAVR is superior to medical therapy for patients with severe native aortic valve stenosis at increased surgical risk. METHODS: The CoreValve U.S. Expanded Use Study was a prospective, nonrandomized study that enrolled 233 patients with symptomatic SVF who were deemed unsuitable for reoperation...
May 22, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28516313/dynamic-changes-in-aortic-impedance-after-transcatheter-aortic-valve-replacement-and-its-impact-on-exploratory-outcome
#8
Yukari Kobayashi, Juyong B Kim, Kegan J Moneghetti, Yuhei Kobayashi, Ran Zhang, Daniel A Brenner, Ryan O'Malley, Ingela Schnittger, Michael Fischbein, D Craig Miller, Alan C Yeung, David Liang, Francois Haddad, William F Fearon
Valvulo-arterial impedance (Zva) has been shown to predict worse outcome in medically managed aortic stenosis (AS) patients. We aimed to investigate the association between Zva and left ventricular (LV) adaptation and to explore the predictive value of Zva for cardiac functional recovery and outcome after transcatheter aortic valve replacement (TAVR). We prospectively enrolled 128 patients with AS who underwent TAVR. Zva was calculated as: (systolic blood pressure + mean transaortic gradient)/stroke volume index)...
May 17, 2017: International Journal of Cardiovascular Imaging
https://www.readbyqxmd.com/read/28511838/supra-annular-valve-in-valve-implantation-reduces-blood-stasis-on-the-transcatheter-aortic-valve-leaflets
#9
Koohyar Vahidkhah, Ali N Azadani
Leaflet thrombosis following transcatheter aortic valve replacement (TAVR) and Valve-in-Valve (ViV) procedures has been increasingly recognized. This study aimed to investigate the effect of positioning of the transcatheter aortic valve (TAV) in ViV setting on the flow dynamics aspect of post-ViV thrombosis by quantifying the blood stasis in the intra-annular and supra-annular settings. To that end, two idealized computational models, representing ViV intra-annular and supra-annular positioning of a TAV were developed in a patient-specific geometry...
May 5, 2017: Journal of Biomechanics
https://www.readbyqxmd.com/read/28510272/diabetes-mellitus-is-associated-with-increased-acute-kidney-injury-and-1-year-mortality-after-transcatheter-aortic-valve-replacement-a-meta-analysis
#10
George S Mina, Priyanka Gill, Demiana Soliman, Pratap Reddy, Paari Dominic
BACKGROUND: Diabetes mellitus (DM) is associated with adverse outcomes after surgical aortic valve replacement. However, there are conflicting data on the impact of DM on outcomes of transcatheter aortic valve replacement (TAVR). HYPOTHESIS: DM is associated with poor outcomes after different cardiac procedures. Therefore, DM can also be associated with poor outcomes after TAVR. METHODS: We searched PubMed and Cochrane Central Register of Controlled Trials for studies that evaluated outcomes after TAVR and stratified at least 1 of the studied endpoints by DM status...
May 16, 2017: Clinical Cardiology
https://www.readbyqxmd.com/read/28500739/feasibility-and-safety-of-transfemoral-sheathless-portico-aortic-valve-implantation-preliminary-results-in-a-single-center-experience
#11
Maurizio Taramasso, Andrea Denegri, Shingo Kuwata, Hans Rickli, Philipp K Haager, Gabor Sütsch, Hector Rodriguez Cetina Biefer, Jan Kottwitz, Fabian Nietlispach, Francesco Maisano
BACKGROUND: Feasibility of transfemoral (TF) transcathteter aortic valve replacement (TAVR) is limited by the smallest diameter, the calcification and tortuosity of the iliofemoral access vessels. The use of the Portico system without delivery sheath results in significantly lower profile delivery system compared to standard technique. We herein report our single center experience, feasibility and safety of such an approach. METHODS: The Portico valve was implanted sheathless in 81 high-risk patients with severe aortic stenosis utilizing percutaneous femoral access...
May 13, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28498562/effect-of-valve-design-and-anticoagulation-strategy-on-30-day-clinical-outcomes-in-transcatheter-aortic-valve-replacement-results-from-the-bravo-3-randomized-trial
#12
Axel Linke, Jaya Chandrasekhar, Samantha Sartori, Thierry Lefevre, Eric van Belle, Ulrich Schaefer, Didier Tchetche, Gennaro Sardella, John Webb, Antonio Colombo, Stephan Windecker, Birgit Vogel, Serdar Farhan, Sabato Sorrentino, Madhav Sharma, Clayton Snyder, Anita Asgar, Nicolas Dumonteil, Corrado Tamburino, Ulrich Hink, Roberto Violini, Pieter Stella, Debra Bernstein, Efthymios Deliargyris, Christian Hengstenberg, Usman Baber, Roxana Mehran, Prodromos Anthopoulos, George Dangas
BACKGROUND: Selection of valve and procedural anticoagulant type may impact bleeding and vascular complications in transfemoral transcatheter aortic valve replacement (TAVR). We sought to compare outcomes by valve [balloon expandable (BE) or non-BE] and anticoagulant [bivalirudin vs. unfractionated heparin (UFH)] type from the BRAVO-3 trial. METHODS: BRAVO-3 was a randomized multicenter trial included 500 BE-TAVR and 282 non-BE TAVR patients, randomized to bivalirudin vs...
May 12, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28497845/comparison-of-dual-antiplatelet-therapy-versus-oral-anticoagulation-following-transcatheter-aortic-valve-replacement-a-retrospective-single-center-registry-analysis
#13
Erik W Holy, Julia Kebernik, Abdelhakim Allali, Mohamed El-Mawardy, Gert Richardt, Mohamed Abdel-Wahab
BACKGROUND: The choice of optimal antithrombotic regimen after transcatheter aortic valve replacement (TAVR) remains a matter of debate. The objective of this study was to compare both efficacy and safety outcomes based on the type of antithrombotic therapy prescribed after TAVR METHODS: This is a retrospective analysis of 514 consecutive patients treated with either dual antiplatelet therapy (DAPT) (n = 315; 61.3%) or oral anticoagulation (OAC) plus clopidogrel (n = 199; 38.7%) for a minimum of 3 month after TAVR followed by antiplatelet monotherapy or OAC only, respectively...
May 12, 2017: Cardiology Journal
https://www.readbyqxmd.com/read/28495894/morbidity-and-mortality-associated-with-balloon-aortic-valvuloplasty-a-national-perspective
#14
Mohamad Alkhouli, Chad J Zack, Mohammad Sarraf, Riyaz Bashir, Rick A Nishimura, Mackram F Eleid, Vuyisile T Nkomo, Gurpreet S Sandhu, Rajiv Gulati, Kevin L Greason, David R Holmes, Charanjit S Rihal
BACKGROUND: The introduction of transcatheter aortic valve replacement (TAVR) led to renewed interest in balloon aortic valvuloplasty (BAV). We sought to assess contemporary trends in BAV utilization and their outcomes. METHODS AND RESULTS: The Nationwide Inpatient Sample was used to identify patients who underwent BAV between 2004 and 2013. In-hospital morbidity and mortality, and predictors of death after BAV were assessed. Outcomes of propensity-matched groups of patients undergoing elective BAV or TAVR were evaluated...
May 2017: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28495211/maximum-aortic-valve-opening-phase-for-annulus-sizing-in-pre-tavr-cta
#15
Nam Ju Lee, Saurabh Jha, Bong Ju Lee, Harold Litt
RATIONALE AND OBJECTIVES: The optimal phase for the measurement of the aortic annular area for transcatheter aortic valve replacement (TAVR) is not standardized, although most agree that systolic measurements are preferred, when the annulus is larger. We hypothesized that the maximum annular area occurs at the cardiac phase of the maximum aortic valve opening (MAVO) and that this phase can be accurately and reproducibly assessed by visual inspection only. MATERIALS AND METHODS: The aortic valve opening area was inspected visually by two readers to determine the MAVO phase...
May 8, 2017: Academic Radiology
https://www.readbyqxmd.com/read/28494713/vascular-complications-associated-with-transcatheter-aortic-valve-replacement
#16
M Rizwan Sardar, Andrew M Goldsweig, J Dawn Abbott, Barry L Sharaf, Paul C Gordon, Afshin Ehsan, Herbert D Aronow
Transcatheter aortic valve replacement (TAVR) is now an accepted pathway for aortic valve replacement for patients who are at prohibitive, severe and intermediate risk for traditional aortic valve surgery. However, with this rising uptrend and adaptation of this new technology, vascular complications and their management remain an Achilles heel for percutaneous aortic valve replacement. The vascular complications are an independent predictor of mortality for patients undergoing TAVR. Early recognition of these complications and appropriate management is paramount...
June 2017: Vascular Medicine
https://www.readbyqxmd.com/read/28494061/association-between-hospital-volume-and-30-day-readmissions-following-transcatheter-aortic-valve-replacement
#17
Sahil Khera, Dhaval Kolte, Tanush Gupta, Andrew Goldsweig, Poonam Velagapudi, Ankur Kalra, Gilbert H L Tang, Wilbert S Aronow, Gregg C Fonarow, Deepak L Bhatt, Herbert D Aronow, Neal S Kleiman, Michael Reardon, Paul C Gordon, Barry Sharaf, J Dawn Abbott
Importance: With the approval of transcatheter aortic valve replacement (TAVR) for patients with severe symptomatic aortic stenosis at intermediate surgical risk, TAVR volume is projected to increase exponentially in the United States. The 30-day readmission rate for TAVR was recently reported at 17.9%. The association between institutional TAVR volume and the 30-day readmission metric has not been examined. Objective: To assess the association between hospital TAVR volume and 30-day readmission...
May 11, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/28493641/impact-of-pre-existing-or-new-onset-atrial-fibrillation-on-30-day-clinical-outcomes-following-transcatheter-aortic-valve-replacement-results-from-the-bravo-3-randomized-trial
#18
Christian Hengstenberg, Jaya Chandrasekhar, Samantha Sartori, Thierry Lefevre, Ghada Mikhail, Nicolas Meneveau, Christophe Tron, Raban Jeger, Christian Kupatt, Birgit Vogel, Serdar Farhan, Sabato Sorrentino, Madhav Sharma, Clayton Snyder, Oliver Husser, Peter Boekstegers, Rainer Hambrecht, Julian Widder, David Hildick-Smith, Marco De Carlo, Peter Wijngaard, Efthymios Deliargyris, Debra Bernstein, Usman Baber, Roxana Mehran, Prodromos Anthopoulos, George Dangas
BACKGROUND: Prior studies have suggested that patients with atrial fibrillation (AF) undergoing transcatheter aortic valve replacement (TAVR) are at higher risk for adverse cardiovascular events. Whether procedural bivalirudin compared to unfractionated heparin (UFH) has a beneficial effect on early outcomes in these patients is unknown. We examined for the effect of baseline or new-onset AF within 30 days of TAVR and explored for the effect of bivalirudin vs. UFH by AF status, on 30-day outcomes from the BRAVO 3 trial...
May 11, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28493389/contemporary-transcatheter-aortic-valve-replacement-with-third-generation-balloon-expandable-versus-self-expanding-devices
#19
Toby Rogers, Arie Steinvil, Kyle Buchanan, M Chadi Alraies, Edward Koifman, Jiaxiang Gai, Rebecca Torguson, Petros Okubagzi, Itsik Ben-Dor, Augusto Pichard, Lowell Satler, Ron Waksman
OBJECTIVES: To evaluate balloon-expandable and self-expanding third-generation transcatheter aortic valve replacement (TAVR) devices according to patient selection criteria and outcomes. BACKGROUND: Two competing third-generation TAVR technologies are currently commercially available in the US. There are no published head-to-head comparisons of the relative performance of these two devices. METHODS: 257 consecutive patients undergoing TAVR with a third-generation balloon-expandable (Edwards Sapien 3) or self-expanding device (Medtronic CoreValve Evolut R) at a single US medical center were included...
May 11, 2017: Journal of Interventional Cardiology
https://www.readbyqxmd.com/read/28488404/low-gradient-dismal-outcome-tavr-should-we
#20
EDITORIAL
Samuel M Butman
Low gradient (<40 mm) aortic valve stenosis (AVA < 1.0 cm(2) ) outcomes with TAVR are worse than when gradients are > 40 mm Hg. Concomitant coronary disease, older age, presence of diabetes, and lower ejection fraction in patients with low gradient aortic valve stenosis account for the poorer outcome after TAVR. Historically, similar results have been seen with surgical AVR.
May 2017: Catheterization and Cardiovascular Interventions
keyword
keyword
5226
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"